Cytodyn Inc (CYDY)

[woodenbear]

My understanding for the shorter timeframes and smaller sample sizes is not because FDA is so positive on the drug but because they narrowed the protocol down to a much smaller and sicker group that was failing on at least 3 medicines in SOC. The initial protocol was for many more patients until protocol was narrowed.

My understanding was that CYDY chose to seek the narrower and more restrictive protocol bc they thought they would get ODD... another boneheaded move that management should have known the qualifications before veering the whole ship on off course just like they did with the RS and uplist. They didn’t get ODD...

Management screwed up the size of the trial in the first place by setting it up for 30 people. Obviously they didn’t bother to run that by the FDA who could have told them from the very beginning that they needed 50 for statistical significance...